Portfolio company
Vicebio
United Kingdom · £79.0m raised
Raised
£79.0m
Latest stage
Series B
Rounds recorded
1
Backed by
2 investors
Sectors
About
This biopharmaceutical company develops multivalent vaccines for respiratory viral infections targeting older adults and immunocompromised patients.
SourceFunding history · 1
Similar companies
CoVBio
The company develops broad-spectrum vaccines and therapeutic antibodies to protect the global population against coronaviruses and other respiratory viral infections.
ReViral
This company develops antiviral therapeutics for respiratory syncytial virus to treat pediatric, immunocompromised and elderly patients.
Adagio Therapeutics
This biopharmaceutical company develops monoclonal antibody therapies for the prevention and treatment of viral respiratory diseases, primarily serving immunocompromised patients.
Ab&B Bio-Tech
This company develops human vaccines, including quadrivalent influenza subunit and pneumococcal polysaccharide products, for children, adults and elderly patients.
ViroVet
This company develops vaccines and antiviral drugs for livestock to control respiratory diseases and other viral infections in cattle, swine, sheep and goats.
Pneumagen
This clinical-stage biotech company develops intranasal antiviral drugs to prevent and treat respiratory tract infections for patients with chronic lung diseases.
Vaccitech Ltd
This biopharmaceutical company develops immunotherapeutic products and vaccines for patients with chronic infectious diseases, autoimmune conditions and cancer.
Baseimmune
The company develops AI-designed vaccines and antigens for pharmaceutical partners and biotech researchers to treat infectious diseases and chronic conditions in humans and animals.
